Clinical TrialMay 26, 2026, 04:07 PM
Jade Biosciences Doses First Patient in JADE201 Phase 1 Trial
AI Summary
Jade Biosciences announced the dosing of the first participant in a first-in-human (FIH) Phase 1 clinical trial for JADE201. JADE201 is an investigational, half-life extended, afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFF-R) designed to deplete B cells. The company expects interim FIH data in 2027, which will inform indication prioritization across multiple potential autoimmune indications.
Key Highlights
- Jade Biosciences dosed the first participant in a Phase 1 clinical trial for JADE201.
- JADE201 is an investigational monoclonal antibody targeting BAFF-R for autoimmune diseases.
- The drug is designed to deplete B cells via enhanced effector function and BAFF signal blockade.
- Preclinical data showed dose-dependent BAFF-R occupancy and sustained B cell depletion.
- Interim Phase 1 data in rheumatoid arthritis are expected in 2027.
- The trial will assess JADE201's safety, tolerability, pharmacokinetics, and pharmacodynamics.
Price Impact
More from JBIO